A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
- 15 March 2002
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 29 (1-2), 221-228
- https://doi.org/10.1016/s0731-7085(02)00014-6
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy VolunteersClinical Pharmacokinetics, 2001
- Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancerCancer Gene Therapy, 1999
- Antisense oligonucleotides to the epidermal growth factor receptorBreast Cancer Research and Treatment, 1999
- American Association for Cancer Research 1997: progress and new hope in the fight against cancerExpert Opinion on Investigational Drugs, 1997
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996
- A New Approach for Dealing with the Stability of Drugs in Biological FluidsJournal of Pharmaceutical Sciences, 1985